Retatrutide vs Semaglutide: One Receptor or Three

Semaglutide and retatrutide represent two generations of incretin peptide design. Semaglutide is a selective GLP-1 receptor agonist built on the human GLP-1 sequence. Retatrutide is a single peptide that activates GLP-1, GIP and glucagon receptors. Tirzepatide, a dual GIP/GLP-1 agonist, sits between them, and it is the only one of the three for which a head-to-head trial against semaglutide has been published.

For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.

Key points

Receptor count: semaglutide 1 (GLP-1R); tirzepatide 2; retatrutide 3 (adds GCGR).
All three are lipidated for albumin binding and once-weekly exposure.
Half-lives: semaglutide ~1 week; retatrutide ~6 days.
Retatrutide has not been compared directly with semaglutide in a published trial.
Cross-trial comparisons are indicative only.

The three generations compared

	Semaglutide	Tirzepatide	Retatrutide
Receptors	GLP-1R	GIPR, GLP-1R	GIPR, GLP-1R, GCGR
Sequence basis	Human GLP-1 (Aib8, Arg34), lipidated at Lys26	GIP-based, Aib2/Aib13, lipidated at Lys20	Single tri-agonist peptide
Molecular weight	~4114 g/mol	4813.53 Da	See developer publications
Human half-life	~1 week	~5 days	~6 days
Status	Approved	Approved	Investigational

For research, retatrutide and tirzepatide are available as lyophilized peptides with lot-level HPLC and MS data.

How semaglutide was designed

Semaglutide was developed from liraglutide to achieve once-weekly exposure. It carries two substitutions relative to human GLP-1 (Aib at position 8, Arg at 34) and a fatty-acid moiety on Lys26. Its GLP-1 receptor affinity (0.38 nM) is about three-fold lower than liraglutide’s, but its albumin affinity is higher; plasma half-life in mini-pigs was 46.1 hours after intravenous administration (Lau et al., 2015). In humans, its half-life is about one week (Ikushima et al., 2018).

How retatrutide differs

Retatrutide adds two receptor activities. In vitro its glucagon and GLP-1 receptor activities are balanced, with greater GIP receptor activity. In obese mice, glucagon-receptor-mediated energy expenditure added to the intake-reducing effects of the incretin components (Coskun et al., 2022). Its human half-life of about 6 days, from a phase 1b study, is similar to semaglutide’s (Urva et al., 2022).

Trial endpoints (separate trials)

Trial	Molecule	Population	Duration	Mean body-weight change	Placebo / comparator
STEP 1 (Wilding et al., 2021)	Semaglutide	1961 adults, no diabetes	68 weeks	−14.9%	−2.4% placebo
Phase 3 obesity (Jastreboff et al., 2026)	Retatrutide	2339 adults, no diabetes	80 weeks	−17.6% to −25.0% (dose groups)	−3.9% placebo
SURMOUNT-5 (Aronne et al., 2025)	Tirzepatide vs semaglutide	751 adults, no diabetes	72 weeks	−20.2% vs −13.7%	Head-to-head

Only SURMOUNT-5 is a direct comparison. The STEP 1 and retatrutide trials differ in duration, population and analysis, so their numbers cannot be ranked directly. A retatrutide-versus-semaglutide trial has not been published.

What the comparison means for researchers

Mechanistic studies: semaglutide isolates GLP-1R effects; tirzepatide adds GIPR; retatrutide adds GCGR. Using them side by side lets the contribution of each receptor be explored.
Analytical work: all three are 4–5 kDa lipidated peptides with similar chromatographic behaviour; confirm identity by high-resolution MS.
Handling: lipidated peptides can self-associate; avoid shaking and repeated freeze–thaw. See how to reconstitute retatrutide and use the peptide reconstitution calculator.

Mechanistic differences in more detail

A single-receptor agonist and a triple agonist differ in more than the number of targets. Semaglutide’s effects can be attributed to GLP-1 receptor signalling, which simplifies interpretation in mechanistic studies. With retatrutide, each observed effect can, in principle, come from GLP-1R, GIPR or GCGR activation, or from their interaction. Glucagon receptor agonism alone tends to raise blood glucose, so the incretin components must offset it. For this reason, retatrutide studies often report glycaemic and hepatic endpoints alongside body weight. Researchers designing comparative experiments sometimes include receptor-selective tool compounds or antagonists to separate these contributions.

Open questions

How would retatrutide and semaglutide compare in a head-to-head trial with the same duration and population?
What fraction of retatrutide’s effects comes from glucagon receptor agonism in humans, as opposed to mice?
How do the long-term safety profiles compare beyond the trial periods published so far?

Structural note

Semaglutide keeps most of the human GLP-1 sequence, which is why its receptor selectivity is high. Tirzepatide starts from the GIP sequence and was tuned to activate the GLP-1 receptor as well. Retatrutide had to be tuned for three receptors at once. In each case the fatty acid, rather than the peptide backbone, is what sets the roughly weekly half-life.

Related research

Frequently asked questions

What is the difference between retatrutide and semaglutide?

Semaglutide is a selective GLP-1 receptor agonist derived from human GLP-1. Retatrutide is a single peptide that activates three receptors: GLP-1, GIP and glucagon.

How do semaglutide, tirzepatide and retatrutide differ?

They activate one, two and three receptors respectively: semaglutide GLP-1; tirzepatide GLP-1 and GIP; retatrutide GLP-1, GIP and glucagon. All three are lipidated for once-weekly exposure.

What are the half-lives of semaglutide and retatrutide?

Semaglutide’s half-life is about one week in humans; retatrutide’s was about 6 days in a phase 1b study.

Has retatrutide been compared directly with semaglutide?

Not in a published head-to-head trial. Tirzepatide has been compared directly with semaglutide in a phase 3b trial.

Does Healthy Welness supply semaglutide?

Semaglutide is not currently offered in our catalogue; retatrutide and tirzepatide are available as research peptides.

References

Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015. PMID: 26308095 https://pubmed.ncbi.nlm.nih.gov/26308095/
Ikushima I, et al. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Adv Ther. 2018. PMID: 29536338 https://pubmed.ncbi.nlm.nih.gov/29536338/
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185 https://pubmed.ncbi.nlm.nih.gov/33567185/
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022. PMID: 35985340 https://pubmed.ncbi.nlm.nih.gov/35985340/
Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. PMID: 36354040 https://pubmed.ncbi.nlm.nih.gov/36354040/
Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954 https://pubmed.ncbi.nlm.nih.gov/42814954/
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. PMID: 40353578 https://pubmed.ncbi.nlm.nih.gov/40353578/